Thursday 6-12-2014 Galena Biopharma (GALE) $GALE o
Post# of 88
Posted On: 06/12/2014 10:26:55 PM
Thursday 6-12-2014 Galena Biopharma (GALE) $GALE opened at 3.21 hitting the high price of 3.38 and a day low of 3.09 with a total volume of 7,681,515. GALE had a previous close of 3.25 and has been seeing an average volume of 3,515,750.
Overall Average: 56% Buy
Recent stock forum discussions about GALE http://investorshangout.com/search?q=GALE&...mp;yt0=Go!
Most active Nasdaq-traded stocks
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.: (full story)
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Nektar Therapeutics (NASDAQ: NKTR), CytRx Corporation (NASDAQ: CYTR), Galena Biopharma, Inc. (NASDAQ: GALE) and Receptos, Inc. (NASDAQ: RCPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3633-100free. (full story)
Essential Thrombocythemia - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3tbtlt/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Essential Thrombocythemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Essential Thrombocythemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Essential Thrombocythemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Shire Plc - Incyte Corporation - Galena Biopharma, Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/3tbtlt/essential (full story)
Is It Time to Buy Galena?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 10, 5:11PM CDT
Galena Biopharma shareholders have had a rough 2014 so far, with the stock dipping over 50% from its highs just north of $7 to a recent share price of just over $3. The stock has been plagued by rumors and allegations of share price manipulation... (full story)
Why Achillion Pharmaceuticals, Receptos, and Galena Biopharma Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 10, 4:15PM CDT
The broad-based S&P 500 can't go up every day, can it? No. Unfortunately, no index is going to go straight up, but it's certainly felt that way for a while with the iconic index hitting a fresh all-time closing high in 10 of the past 13... (full story)
Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition
at The Street - Fri Jun 06, 9:32AM CDT
I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail... (full story)
4 Stocks Under $10 to Keep an Eye On
at The Street - Fri Jun 06, 7:56AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. (full story)
Galena Biopharma Presents GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting
GlobeNewswire - Mon Jun 02, 6:19AM CDT
-- Phase 1 study demonstrates GALE-301 (Folate Binding Protein) cancer immunotherapy is well tolerated and induces an immune response in ovarian and endometrial cancer patients. (full story)
Galena Biopharma to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Fri May 30, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the Jefferies 2014 Global Healthcare Conference. The presentation will take place on Thursday, June 5, 2014 at 10:30 a.m. ET in New York City. (full story)
The Seven Deadly Sins of Biotech Investing
at The Street - Thu May 29, 6:00AM CDT
A fool and is money are soon parted, the old idiom goes. I'll add this: The money parting often happens faster to fools who invest in sketchy small-cap biotech stocks. (full story)
Top Gainers Technical Coverage -- Research on NeuStar, Signet Jewelers, Galena Biopharma, and Sarepta Therapeutics
PR Newswire - Fri May 23, 8:29AM CDT
The US markets saw a positive sentiment on Thursday, May 22, 2014, with the NASDAQ Composite closing at 4,154.34, up 0.55%, the Dow Jones Industrial Average ending the session 0.06% higher at 16,543.08, and the S&P 500 edging 0.24% higher to finish the trading session at 1,892.49. During the session gains in the Utilities, Health Care and Consumer Discretionary sectors positively impacted the broader market, while some retraction came in from Energy and Consumer Staples sectors. A number of stocks saw large movements, including NeuStar Inc. (NYSE: NSR), Signet Jewelers Limited (NYSE: SIG), Galena Biopharma Inc. (NASDAQ: GALE) and Sarepta Therapeutics Inc. (NASDAQ: SRPT). Free technical research on NSR, SIG, GALE and SRPT can be downloaded upon signing up at: (full story)
Galena Biopharma to Present at the Marcum MicroCap Conference
GlobeNewswire - Fri May 23, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Ryan Dunlap, Vice President and Chief Financial Officer, will present a corporate update at the Marcum MicroCap Conference. The presentation will take place on Thursday, May 29, 2014 at 10:00 a.m. ET at The Grand Hyatt Hotel in New York City. (full story)
'Mad Money' Lightning Round: I'm Sticking With Con Ed
at The Street - Thu May 22, 5:00AM CDT
Cramer thinks STMicroelectronics is inexpensive but he's not crazy about Amazon or SodaStream. (full story)
Jim Cramer's 'Mad Money' Recap: How Stupid Can This Market Be?
at The Street - Wed May 21, 6:57PM CDT
Cramer thinks higher interest rates are bad for consumers and bad for the markets, not the other way around. (full story)
Galena Biopharma to Present GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting
GlobeNewswire - Wed May 21, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that data from the Company's Phase 1 study with GALE-301, or Folate Binding Protein, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 50 Annual Meeting. (full story)
Could a Vaccine-Based Cancer Cure Be Around the Corner?
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 12:40PM CDT
Whether or not you're an avid follower of the health-care sector, there's always something intriguing and innovative going on. Over the past couple of years we've witnessed one tissue engineering company develop a platform that may one day soon... (full story)
SEC Casting Wide Net in Galena Investigation
at The Street - Wed May 14, 2:35PM CDT
Lion Bio received an SEC subpoena related to the Galena DreamTeam investigation. (full story)
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Why Galena Biopharma Inc. Shares Surged Higher
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galena Biopharma , a biopharmaceutical... (full story)
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria (full story)
Overall Average: 56% Buy
Recent stock forum discussions about GALE http://investorshangout.com/search?q=GALE&...mp;yt0=Go!
Most active Nasdaq-traded stocks
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.: (full story)
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Nektar Therapeutics (NASDAQ: NKTR), CytRx Corporation (NASDAQ: CYTR), Galena Biopharma, Inc. (NASDAQ: GALE) and Receptos, Inc. (NASDAQ: RCPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3633-100free. (full story)
Essential Thrombocythemia - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3tbtlt/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Essential Thrombocythemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Essential Thrombocythemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Essential Thrombocythemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Shire Plc - Incyte Corporation - Galena Biopharma, Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/3tbtlt/essential (full story)
Is It Time to Buy Galena?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 10, 5:11PM CDT
Galena Biopharma shareholders have had a rough 2014 so far, with the stock dipping over 50% from its highs just north of $7 to a recent share price of just over $3. The stock has been plagued by rumors and allegations of share price manipulation... (full story)
Why Achillion Pharmaceuticals, Receptos, and Galena Biopharma Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 10, 4:15PM CDT
The broad-based S&P 500 can't go up every day, can it? No. Unfortunately, no index is going to go straight up, but it's certainly felt that way for a while with the iconic index hitting a fresh all-time closing high in 10 of the past 13... (full story)
Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition
at The Street - Fri Jun 06, 9:32AM CDT
I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail... (full story)
4 Stocks Under $10 to Keep an Eye On
at The Street - Fri Jun 06, 7:56AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. (full story)
Galena Biopharma Presents GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting
GlobeNewswire - Mon Jun 02, 6:19AM CDT
-- Phase 1 study demonstrates GALE-301 (Folate Binding Protein) cancer immunotherapy is well tolerated and induces an immune response in ovarian and endometrial cancer patients. (full story)
Galena Biopharma to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Fri May 30, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the Jefferies 2014 Global Healthcare Conference. The presentation will take place on Thursday, June 5, 2014 at 10:30 a.m. ET in New York City. (full story)
The Seven Deadly Sins of Biotech Investing
at The Street - Thu May 29, 6:00AM CDT
A fool and is money are soon parted, the old idiom goes. I'll add this: The money parting often happens faster to fools who invest in sketchy small-cap biotech stocks. (full story)
Top Gainers Technical Coverage -- Research on NeuStar, Signet Jewelers, Galena Biopharma, and Sarepta Therapeutics
PR Newswire - Fri May 23, 8:29AM CDT
The US markets saw a positive sentiment on Thursday, May 22, 2014, with the NASDAQ Composite closing at 4,154.34, up 0.55%, the Dow Jones Industrial Average ending the session 0.06% higher at 16,543.08, and the S&P 500 edging 0.24% higher to finish the trading session at 1,892.49. During the session gains in the Utilities, Health Care and Consumer Discretionary sectors positively impacted the broader market, while some retraction came in from Energy and Consumer Staples sectors. A number of stocks saw large movements, including NeuStar Inc. (NYSE: NSR), Signet Jewelers Limited (NYSE: SIG), Galena Biopharma Inc. (NASDAQ: GALE) and Sarepta Therapeutics Inc. (NASDAQ: SRPT). Free technical research on NSR, SIG, GALE and SRPT can be downloaded upon signing up at: (full story)
Galena Biopharma to Present at the Marcum MicroCap Conference
GlobeNewswire - Fri May 23, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Ryan Dunlap, Vice President and Chief Financial Officer, will present a corporate update at the Marcum MicroCap Conference. The presentation will take place on Thursday, May 29, 2014 at 10:00 a.m. ET at The Grand Hyatt Hotel in New York City. (full story)
'Mad Money' Lightning Round: I'm Sticking With Con Ed
at The Street - Thu May 22, 5:00AM CDT
Cramer thinks STMicroelectronics is inexpensive but he's not crazy about Amazon or SodaStream. (full story)
Jim Cramer's 'Mad Money' Recap: How Stupid Can This Market Be?
at The Street - Wed May 21, 6:57PM CDT
Cramer thinks higher interest rates are bad for consumers and bad for the markets, not the other way around. (full story)
Galena Biopharma to Present GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting
GlobeNewswire - Wed May 21, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that data from the Company's Phase 1 study with GALE-301, or Folate Binding Protein, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 50 Annual Meeting. (full story)
Could a Vaccine-Based Cancer Cure Be Around the Corner?
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 12:40PM CDT
Whether or not you're an avid follower of the health-care sector, there's always something intriguing and innovative going on. Over the past couple of years we've witnessed one tissue engineering company develop a platform that may one day soon... (full story)
SEC Casting Wide Net in Galena Investigation
at The Street - Wed May 14, 2:35PM CDT
Lion Bio received an SEC subpoena related to the Galena DreamTeam investigation. (full story)
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Why Galena Biopharma Inc. Shares Surged Higher
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galena Biopharma , a biopharmaceutical... (full story)
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria (full story)
(0)
(0)SELLAS Life Sciences Group, Inc. (SLS) Stock Research Links
Scroll down for more posts ▼